Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech Inc. (IOBT) is a clinical-stage biopharmaceutical leader developing T-win platform-based cancer immunotherapies. This dedicated news hub provides investors and researchers with verified updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Access real-time announcements about IO Biotech's innovative pipeline targeting immune inhibitory pathways, including IDO and PD-L1-focused therapies. Our curated collection features earnings reports, research publications, and corporate developments directly from company filings and authorized sources.
Key updates include phase trial results, FDA communications, intellectual property advancements, and executive team announcements. Bookmark this page for streamlined tracking of IO Biotech's progress in advancing novel cancer treatments through methodical clinical evaluation.
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences. The company's senior management will provide corporate updates and engage in one-on-one meetings at these events:
1. Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 4, 2024. CEO Mai-Britt Zocca, PhD, will participate in a fireside chat at 5:35 pm ET.
2. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024. CFO Amy Sullivan will present at 10:30 am ET.
Webcasts of both presentations will be available on IO Biotech's website for 90 days following the events.
IO Biotech (Nasdaq: IOBT) reported Q2 2024 financial results and business highlights. Key points include:
1. Phase 3 interim analysis for IO102-IO103 in advanced melanoma expected in Q3 2024.
2. Completed enrollment in Phase 2 trials for NSCLC and SCCHN.
3. Data from SCCHN cohort accepted for ESMO 2024 presentation.
4. Ended Q2 with $100.7 million in cash, expected to support operations into Q4 2025.
5. Net loss of $20.7 million for Q2 2024, compared to $21.2 million in Q2 2023.
6. R&D expenses decreased to $15.8 million from $16.5 million year-over-year.
7. G&A expenses increased to $5.7 million from $5.3 million year-over-year.
IO Biotech (Nasdaq: IOBT) announced that an abstract on their lead therapeutic cancer vaccine candidate, IO102-IO103, has been accepted for poster presentation at the ESMO Congress 2024. The presentation will showcase data from a completed cohort of squamous cell carcinoma of the head and neck (SCCHN) patients in a Phase 2 basket trial combining IO102-IO103 with pembrolizumab.
The poster, titled 'A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)', will be presented on September 14, 2024, at the congress in Barcelona. This data represents a significant step in exploring IO102-IO103's potential across various solid tumors with high unmet medical needs.
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, announced its participation at the Jefferies Global Healthcare Conference, occurring from June 4-6, 2024, in New York, NY.
The company's President and CEO, Mai-Britt Zocca, Ph.D., will present on June 5, 2024, from 7:30-7:55 AM EST, discussing IO Biotech’s development of novel cancer vaccines using their T-win® platform.
Additionally, both Dr. Zocca and CFO Amy Sullivan will engage in one-on-one meetings with investors during the conference. A webcast of the presentation will be available on the company's website for 90 days.
IO Biotech has reported its financial results for Q1 2024, highlighting a net loss of $19.5 million, up from $17.0 million in Q1 2023. Research and development expenses increased to $14.3 million, attributed to clinical trial activities for its cancer vaccine candidate, IO102-IO103. General and administrative expenses slightly decreased to $5.9 million. The company ended the quarter with $118 million in cash, down from $143.2 million in December 2023.
Key developments include the completion of patient enrollment in the pivotal Phase 3 trial of IO102-IO103 in combination with pembrolizumab for advanced melanoma. The interim analysis for the overall response rate (ORR) is expected in Q3 2024, and the primary endpoint of progression-free survival (PFS) in H1 2025. Additionally, Phase 2 trials IOB-022 and IOB-032 have progressed, with significant enrollment milestones achieved. The executive team has been strengthened with new hires to enhance business and commercial development.
FAQ
What is the current stock price of Io Biotech (IOBT)?
What is the market cap of Io Biotech (IOBT)?
